Prostate cancer drug not prescribed because of cost

The Prostate Cancer Charity says that some men are being denied the drug docetaxel (Taxotere) simply on cost grounds.

Prostate cancer cells
Prostate cancer cells
Docetaxel was first licensed for the treatment of breast cancer, but was found to improveoverall survival, compared with the standard treatments, in patients with prostate cancer who had not responded to hormone therapy

NICE approved the use of docetaxel in June of this year, but a course of treatment costs approximately £7,000.

John Neate, chief executive of the Prostate Cancer Charity told the BBC: ‘It cannot be acceptable that men and their families who are already having to deal with the tough news of a prostate cancer diagnosis, have to wrestle with NHS bureaucracy at the same time.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us:

Just published

Medical examiners to scrutinise deaths in community settings

The MDU's Dr Kathryn Leask explains how the expansion of the medical examiner system...

Person receiving a COVID-19 booster

COVID-19 booster campaign to start on 5 September, NHS England says

The COVID-19 booster programme will begin in care homes and for housebound patients...

GP consulting room

Nine in ten GPs fear their practice will struggle to cope this winter

Nearly nine in ten GPs fear that their practice will struggle to cope this winter,...

BMA sign

BMA elects new deputy chair of England GP committee and chair of Scottish council

Dr David Wrigley has been elected as new deputy chair of the BMA's GP committee in...

UK money

Almost half of practices say income from private fees has fallen in past year

Almost half of GP practices have seen their income from private and professional...

COVID-19 vaccination centre

BMA raises 'serious concerns' about GP workload and funding for autumn COVID boosters

The BMA has raised 'serious concerns' about the workload implications of this autumn's...